Neurological
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (BHV7000-201)
This is a Phase 2, global, multicenter, long-term safety study designed to assess the safety and tolerability of BHV-7000 in participants with focal refractory epilepsy. Approximately 660 eligible subjects will enter this study after completing the DBP of either the BHV7000-302 or BHV7000- 303 studies.
In the opinion of the investigator, subjects must have tolerated BHV7000/placebo, during participation in the DBP of the parent studies, BHV7000-302 or BHV7000-303 to be eligible.
Eligible subjects who completed the DBP of the BHV7000-302 study will ...
GO TO STUDY